The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children

被引:50
|
作者
Walker, A. Sarah
Mulenga, Veronica
Ford, Deborah
Kabamba, Desire
Sinyinza, Frederick
Kankasa, Chipepo
Chintu, Chifumbe
Gibb, Diana M.
机构
[1] MRC, Clin Trials Unit, London NW1 2DA, England
[2] Univ Teaching Hosp, Lusaka, Zambia
基金
英国医学研究理事会;
关键词
D O I
10.1086/515396
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Data on the population effectiveness of cotrimoxazole prophylaxis and antiretroviral therapy ( ART) in human immunodeficiency virus (HIV)-infected African children are few Methods. A total of 534 Zambian children with HIV infection were randomized to receive daily cotrimoxazole prophylaxis or placebo in the Children with HIV Antibiotic Prophylaxis trial. Following trial closure, children who received the placebo initiated cotrimoxazole prophylaxis, and all children were observed in a closed cohort. Mortality and hospital admission rates were compared, over calendar time, in 9-month periods: trial recruitment (March 2001 to April 2002, May 2002 to January 2003), trial follow-up to closure (February 2003 to October 2003), initial follow-up posttrial ( November 2003 to July 2004), and early and later ART availability (August 2004 to April 2005, and May 2005 to May 2006, respectively). Results. A total of 546 child-years of follow-up, 40 deaths, and 80 hospital admissions were observed between the time of trial closure and June 2006. A total of 117 of 283 children who were alive at trial closure received ART in the posttrial period (median child age at first use of ART, 8.8 years). Rates decreased in both groups during the trial period, suggesting a survivorship effect. Mortality and hospital admission rates before trial closure were 14 (95% confidence interval [CI], 9-21) deaths per 100 child-years and 24 (95% CI, 15-39) hospital admissions per 100 child-years, respectively, for children who were receiving cotrimoxazole, and were 23 (95% CI, 16-34) deaths per 100 child-years and 35 ( 95% CI, 23-53) hospital admissions per 100 child-years, respectively, for children who were receiving the placebo. After trial closure, rates remained stable in the cotrimoxazole group, but decreased to 15 ( 95% CI, 8-26) deaths per 100 child-years and 19 (95% CI, 10-41) hospital admissions per 100 child-years, respectively, for the group of children who received placebo and then initiated cotrimoxazole prophylaxis. In both groups combined, mortality rates decreased to 6 (95% CI, 3-11) deaths per 100 child-years and then 2 ( 95% CI,0.8-6) deaths per 100 child-years during periods of ART availability; hospital admission rates decreased to 17 ( 95% CI, 11-27) hospital admissions per 100 child-years and 8 (95% CI, 4-15) hospital admissions per 100 child-years, respectively. Conclusion. The benefits of once- daily cotrimoxazole prophylaxis continued throughout the trial and after trial closure. Mortality and hospital admissions decreased (by > 6-fold and similar to 3-fold, respectively) following ART availability, similar to findings observed in resource- rich countries.
引用
收藏
页码:1361 / 1367
页数:7
相关论文
共 50 条
  • [31] Guideline for Antiretroviral Therapy of HIV-Infected Children and Adolescents
    Neubert, J.
    Niehues, T.
    Baumann, U.
    Buchholz, B.
    Notheiss, G.
    Wintergerst, U.
    Blume, J.
    Feiterna-Sperling, C.
    Laws, H. -J
    Linde, R.
    Koenigs, C.
    [J]. KLINISCHE PADIATRIE, 2012, 224 (02): : 98 - 110
  • [32] Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
    Mantes Gil, Am Cecilia
    Lorenzetti, Raquel
    Mendes, Gun Bergsten
    Morcillo, Andre Moreno
    Dalbo Contreras Toro, Adyleia Aparecida
    Nolasco do Silva, Marcos Tadeu
    dos Santos Vilela, Maria Marluce
    [J]. SAO PAULO MEDICAL JOURNAL, 2007, 125 (04): : 205 - 209
  • [33] When to initiate antiretroviral therapy in HIV-infected children?
    Thuret, I
    [J]. ARCHIVES DE PEDIATRIE, 2004, 11 (12): : 1521 - 1524
  • [34] Metabolic complications of antiretroviral therapy in HIV-infected children
    Eley, Brian
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (01) : 37 - 49
  • [35] Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children
    Gray, Diane M.
    Zar, Heather
    Cotton, Mark
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [36] Predictors of mortality among HIV-infected children receiving highly active antiretroviral therapy
    Nlend, A. E. Njom
    Loussikila, A. B.
    [J]. MEDECINE ET MALADIES INFECTIEUSES, 2017, 47 (01): : 32 - 37
  • [37] Mortality and Clinical Outcomes in HIV-Infected Children on Antiretroviral Therapy in Malawi, Lesotho, and Swaziland
    Kabue, Mark M.
    Buck, W. Chris
    Wanless, Sebastian R.
    Cox, Carrie M.
    McCollum, Eric D.
    Caviness, A. Chantal
    Ahmed, Saeed
    Kim, Maria H.
    Thahane, Lineo
    Devlin, Andrew
    Kochelani, Duncan
    Kazembe, Peter N.
    Calles, Nancy R.
    Mizwa, Michael B.
    Schutze, Gordon E.
    Kline, Mark W.
    [J]. PEDIATRICS, 2012, 130 (03) : E591 - E599
  • [38] Cofactors of Mortality Among Hospitalized HIV-Infected Children Initiating Antiretroviral Therapy in Kenya
    Njuguna, Irene N. p
    Cranmer, Lisa M.
    Wagner, Anjuli D.
    LaCourse, Sylvia M.
    Mugo, Cyrus
    Benki-Nugent, Sarah
    Richardson, Barbra A.
    Stern, Joshua
    Maleche-Obimbo, Elizabeth
    Wamalwa, Dalton C.
    John-Stewart, Grace
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 (02) : 138 - 144
  • [39] LEVAMISOLE TREATMENT IN HIV-INFECTED ZAMBIAN CHILDREN
    GARZON, MC
    MUBITA, M
    KACHINKA, L
    [J]. LANCET, 1992, 340 (8827): : 1099 - 1100
  • [40] Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients
    Martín-Carbonero, L
    Soriano, V
    Valencia, E
    García-Samaniego, J
    López, M
    González-Lahoz, J
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (16) : 1467 - 1471